Open-label, Phase II Study of Ladiratuzumab Vedotin (LV) for Castration-Resistant Prostate Cancer (SGNLVA-005, Trial-in-progress).
JOURNAL OF CLINICAL ONCOLOGY(2021)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要
JOURNAL OF CLINICAL ONCOLOGY(2021)